Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review,        editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name
E-mail
Phone
Title
Content
Verification Code
x Close Forever Close
Volume 36 Issue 4
. 
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Pharmaceutical Practice and Service  > 2018  >  36(4): 373-378

WU Sifan, TAN Changyu, FAN Hongbin, YIN Xiaoxing, LU Qian. A Meta-analysis for the evaluation of efficacy and safety of oxcarbazepine and carbamazepine for post-stroke epilepsy[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(4): 373-378. doi: 10.3969/j.issn.1006-0111.2018.04.020
Citation: WU Sifan, TAN Changyu, FAN Hongbin, YIN Xiaoxing, LU Qian. A Meta-analysis for the evaluation of efficacy and safety of oxcarbazepine and carbamazepine for post-stroke epilepsy[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(4): 373-378. doi: 10.3969/j.issn.1006-0111.2018.04.020
shu

A Meta-analysis for the evaluation of efficacy and safety of oxcarbazepine and carbamazepine for post-stroke epilepsy

doi: 10.3969/j.issn.1006-0111.2018.04.020
  • 1.

    Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou 221004, China

  • 2.

    Department of Neurology, Affiliated Hospital of Xuzhou Medical University, Xuzhou 221006, China

  • Received Date: 2017-10-19
  • Rev Recd Date: 2018-03-26
  • Objective To evaluate the efficacy and safety of oxcarbazepine and carbamazepine in treating post-stroke epilepsy. Methods PubMed, Cochrane Library, EMbase, VIP, CNKI and CBM were used for searching literatures related to oxcarbazepine and carbamazepine in the treatment of post-stroke epilepsy before August 2017, followed with RevMan5.3 software for data analysis. Results 6 studies were included with 517 patients. Meta-analysis showed that the total effective rate in oxcarbazepine group was higher than carbamazepine group with statistical significance (RR=1.44,95%CI:1.29~1.60,P<0.000 01). The incidence of total adverse reactions in oxcarbazepine group was also statistically significant lower than carbamazepine group (RR=0.39,95%CI:0.26~0.57,P<0.000 01). There was no statistically significant difference (P>0.05) in rash, dizziness, somnolence, nausea and vomiting between two groups. Conclusion Our analysis indicated that oxcarbazepine had better efficacy than carbamazepine in treating post-stroke epilepsy with less adverse reactions. Due to the limited number of literatures and sample size, large samples with multi-center and high quality clinical randomized controlled trials are needed to confirm the credibility of our conclusions.
  • [1] ZELANO J. Poststroke epilepsy:update and future directions[J]. Ther Adv Neurol Disord,2016,9(5):424-435.
    [2] ZELANO J,LUNDBERG RG,BAARS L,et al. Clinical course of poststroke epilepsy:a retrospective nested case-control study[J]. Brain Behav,2015,5(9):e00366.
    [3] 中华医学会神经病学分会脑电图与癫痫学组. 抗癫痫药物应用专家共识[J].中华神经科杂志,2011,44(1):20-21.
    [4] 杨丹. 奥卡西平和卡马西平治疗脑卒中后继发性癫痫的疗效对比和康复分析[J]. 中国伤残医学,2017,25(1):49-50.
    [5] 侯蕴祈. 奥卡西平与卡马西平单药治疗脑梗死后迟发型癫痫的对照研究[J]. 中国当代医药,2010,17(15):52-53.
    [6] 丁年东. 奥卡西平与卡马西平治疗脑卒中后继发性癫痫的疗效对比观察[J]. 临床合理用药杂志,2016,9(24):42-43.
    [7] 马刚. 奥卡西平与卡马西平治疗脑卒中后继发性癫痫对比研究[J]. 中国实用神经疾病杂志,2015,18(14):24-25.
    [8] 王艳,赵新利,吴新艳,等. 奥卡西平与卡马西平治疗脑卒中后继发性癫痫疗效比较[J].新乡医学院学报,2014,31(4):312-314.
    [9] 韦韬,邱小鹰,陈红,等. 奥卡西平与卡马西平在脑卒中后继发性癫痫的疗效观察[J]. 医学信息,2016,29(9):267-267.
    [10] SZOEKE CE,NEWTON M,WOOD JM,et al. Update on pharmacogenetics in epilepsy:a brief review[J]. Lancet Neurol,2006,5(2):189-196.
    [11] BOOTSMA HP,RICKER L,DIEPMAN L,et al. Levetiracetam in clinical practice:long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center[J]. Epilepsy Behav,2007,10(2):296-303.
    [12] ROUAN MC,LECAILLON JB,GODBILLON J,et al. The effect of renal impairment on the pharmacokinetics of oxcarbazepine and its metabolites[J]. Eur J Clin Pharmacol,1994,47(2):161-167.
    [13] ANTUNES NJ,VAN DIJKMAN SC,LANCHOTE VL,et al. Population pharmacokinetics of oxcarbazepine and its metabolite 10-hydroxycarbazepine in healthy subjects[J]. Eur J Pharm Sci,2017,109S:S116-S123.
    [14] RYVLIN P,MONTAVONT A,NIGHOGHOSSIAN N. Optimizing therapy of seizures in stroke patients[J]. Neurology,2006,67(4):3-9.
  • 加载中

  • Cited by

    Periodical cited type(12)

    1. 郭明迪，刘姿瑶，张小倩，阎丽媚. 基于“久病入络”理论探讨通窍活血汤对缺血性卒中后继发性癫痫的疗效及脑血流动力学的影响. 辽宁中医杂志. 2024(02): 106-110 .
    2. 郭鸿. 拉莫三嗪与奥卡西平治疗成年人局灶性癫痫的疗效比较. 现代诊断与治疗. 2024(06): 856-857+874 .
    3. 何娜，宋旺，刘晓蓉，黎冰梅，石奕武. HLA-A、B基因型与卡马西平、奥卡西平致斑丘疹的相关性分析. 癫痫杂志. 2022(02): 108-115 .
    4. 钱玉芹. 卡马西平联合丁苯酞软胶囊对脑卒中后癫痫患者认知功能的影响. 医药论坛杂志. 2021(01): 90-93 .
    5. 安太健. 脑卒中后继发癫痫应用奥卡西平治疗的效果及安全性分析. 中国现代药物应用. 2021(05): 100-103 .
    6. 李月红，黄华，陈步枢. 奥卡西平与卡马西平治疗脑卒中后癫痫的临床效果比较. 临床合理用药杂志. 2021(16): 62-63 .
    7. 郭芳. 维生素B_(12)与奥卡西平联合治疗脑卒中后癫痫患者的疗效及对非对称性二甲基精氨酸、单核细胞趋化因子-1水平的影响. 中国药物经济学. 2021(08): 85-87+95 .
    8. 张恒. 卡马西平联合苯巴比妥对癫痫患者认知功能及不良反应的影响. 现代诊断与治疗. 2020(05): 718-720 .
    9. 徐婷婷. 丙戊酸钠治疗脑卒中后继发性癫痫的疗效观察. 现代诊断与治疗. 2020(14): 2232-2234 .
    10. 刘丽娇. 丁苯酞软胶囊联合卡马西平治疗脑卒中后癫痫患者的临床疗效分析. 现代诊断与治疗. 2020(14): 2242-2244 .
    11. 王继芬，肖春霞，饶丹，李太银. 奥卡西平与卡马西平治疗贵州少数民族儿童部分性癫痫的对比研究. 医药论坛杂志. 2020(06): 53-55+60 .
    12. 张利山. 缺血性脑卒中后癫痫发作的临床特点及治疗研究. 医学信息. 2019(18): 38-40 .

    Other cited types(0)

通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索
Get Citation
PDF
XML

Article Metrics

Article views(3746) PDF downloads(526) Cited by(12)

Related
Proportional views

A Meta-analysis for the evaluation of efficacy and safety of oxcarbazepine and carbamazepine for post-stroke epilepsy

doi: 10.3969/j.issn.1006-0111.2018.04.020
  • 1. Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou 221004, China
  • 2. Department of Neurology, Affiliated Hospital of Xuzhou Medical University, Xuzhou 221006, China
  • Received Date: 2017-10-19
  • Rev Recd Date: 2018-03-26

Abstract: Objective To evaluate the efficacy and safety of oxcarbazepine and carbamazepine in treating post-stroke epilepsy. Methods PubMed, Cochrane Library, EMbase, VIP, CNKI and CBM were used for searching literatures related to oxcarbazepine and carbamazepine in the treatment of post-stroke epilepsy before August 2017, followed with RevMan5.3 software for data analysis. Results 6 studies were included with 517 patients. Meta-analysis showed that the total effective rate in oxcarbazepine group was higher than carbamazepine group with statistical significance (RR=1.44,95%CI:1.29~1.60,P<0.000 01). The incidence of total adverse reactions in oxcarbazepine group was also statistically significant lower than carbamazepine group (RR=0.39,95%CI:0.26~0.57,P<0.000 01). There was no statistically significant difference (P>0.05) in rash, dizziness, somnolence, nausea and vomiting between two groups. Conclusion Our analysis indicated that oxcarbazepine had better efficacy than carbamazepine in treating post-stroke epilepsy with less adverse reactions. Due to the limited number of literatures and sample size, large samples with multi-center and high quality clinical randomized controlled trials are needed to confirm the credibility of our conclusions.

WU Sifan, TAN Changyu, FAN Hongbin, YIN Xiaoxing, LU Qian. A Meta-analysis for the evaluation of efficacy and safety of oxcarbazepine and carbamazepine for post-stroke epilepsy[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(4): 373-378. doi: 10.3969/j.issn.1006-0111.2018.04.020
Citation: WU Sifan, TAN Changyu, FAN Hongbin, YIN Xiaoxing, LU Qian. A Meta-analysis for the evaluation of efficacy and safety of oxcarbazepine and carbamazepine for post-stroke epilepsy[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(4): 373-378. doi: 10.3969/j.issn.1006-0111.2018.04.020
shu

    HTML

Reference (14)

Catalog

  • HTML

版权所有：《药学实践与服务》编辑委员会

Supervisor & Sponsors: Address: No 325 Guohe Road, ShanghaiPost Code: 200433

Tel: （021）81871324,81871397 E-mail: yxsjzzs@163.com

网站备案号 沪ICP备05003363号-1

Supported by: Beijing Renhe Information Technology Co., Ltd.  

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return